Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Dharmacon, On-Target

Premium

CombiMatrix has introduced a program, called siRNA Solutions, offering customers and collaborators an integrated siRNA gene silencing service for drug discovery. SiRNA Solutions will enable researchers to design and synthesize custom siRNA pools, and help researchers design, conduct, validat, and reiterate gene silencing experiments in days for any gene in any organism, the company said.

 

Dharmacon introduced last week new siRNAs, called On-Target, in which the sense strand of the oligo has been inactivated but the efficacy of the antisense strand maintained.

“SiRNAs are not as specific as we thought they were, so there are off-target effects and the siRNA can hit multiple genes,” Steve Scaringe, Dharmacon’s co-chairman and chief scientific officer, said. “What this product does is address perhaps one of the … major causes of non-specific effects.” Scaringe said that Dharmacon found that “putting a couple [of] modifications on the five prime end” of the dsRNA’s sense strand would inactivate it, keep the antisense strand functional, and reduce by half the potential for off-target effects.

 

Additionally, On-Target will carry a slightly higher price tag than Dharmacon’s regular siRNAs, roughly $75 more per order regardless of unit size, so while it may be useful to some people, others may be satisfied with what they have already and not willing to pay the extra cost, he said.

 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.